日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Ashbya gossypii Protein ROT1 (ROT1), partial CSB-YP748356DOT1
CSB-EP748356DOT1
CSB-BP748356DOT1
CSB-MP748356DOT1
CSB-EP748356DOT1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Ribosome biogenesis protein ALB1 (ALB1) CSB-YP748357DOT
CSB-EP748357DOT
CSB-BP748357DOT
CSB-MP748357DOT
CSB-EP748357DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Protein translation factor SUI1 (SUI1A) CSB-YP748358DOT
CSB-EP748358DOT
CSB-BP748358DOT
CSB-MP748358DOT
CSB-EP748358DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Actin cytoskeleton-regulatory complex protein END3 (END3) CSB-YP748359DOT
CSB-EP748359DOT
CSB-BP748359DOT
CSB-MP748359DOT
CSB-EP748359DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Regulator of rDNA transcription 14 (RRT14) CSB-YP748360DOT
CSB-EP748360DOT
CSB-BP748360DOT
CSB-MP748360DOT
CSB-EP748360DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii pH-response regulator protein palA/RIM20 (RIM20), partial CSB-YP748361DOT
CSB-EP748361DOT
CSB-BP748361DOT
CSB-MP748361DOT
CSB-EP748361DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Mediator of RNA polymerase II transcription subunit 13 (SSN2), partial CSB-YP748362DOT
CSB-EP748362DOT
CSB-BP748362DOT
CSB-MP748362DOT
CSB-EP748362DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Enolase (ENO) CSB-YP748363DOT
CSB-EP748363DOT
CSB-BP748363DOT
CSB-MP748363DOT
CSB-EP748363DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Biogenesis of lysosome-related organelles complex 1 subunit CNL1 (CLN1) CSB-YP748364DOT
CSB-EP748364DOT
CSB-BP748364DOT
CSB-MP748364DOT
CSB-EP748364DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii 37S ribosomal protein MRP10, mitochondrial (MRP10) CSB-YP748365DOT
CSB-EP748365DOT
CSB-BP748365DOT
CSB-MP748365DOT
CSB-EP748365DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Spore membrane assembly protein 2 (SMA2), partial CSB-YP748366DOT1
CSB-EP748366DOT1
CSB-BP748366DOT1
CSB-MP748366DOT1
CSB-EP748366DOT1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Autophagy-related protein 17 (ATG17) CSB-YP748367DOT
CSB-EP748367DOT
CSB-BP748367DOT
CSB-MP748367DOT
CSB-EP748367DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii 40S ribosomal protein S29 (RPS29) CSB-YP748368DOT
CSB-EP748368DOT
CSB-BP748368DOT
CSB-MP748368DOT
CSB-EP748368DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii 37S ribosomal protein S9, mitochondrial (MRPS9), partial CSB-YP748369DOT
CSB-EP748369DOT
CSB-BP748369DOT
CSB-MP748369DOT
CSB-EP748369DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Histone H2A.2 (HTA2) CSB-YP748370DOT
CSB-EP748370DOT
CSB-BP748370DOT
CSB-MP748370DOT
CSB-EP748370DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Orotidine 5'-phosphate decarboxylase (URA3) CSB-YP748371DOT
CSB-EP748371DOT
CSB-BP748371DOT
CSB-MP748371DOT
CSB-EP748371DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii GPI ethanolamine phosphate transferase 1 (MCD4), partial CSB-YP748372DOT
CSB-EP748372DOT
CSB-BP748372DOT
CSB-MP748372DOT
CSB-EP748372DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii 3-ketodihydrosphingosine reductase TSC10 (TSC10), partial CSB-YP748373DOT1
CSB-EP748373DOT1
CSB-BP748373DOT1
CSB-MP748373DOT1
CSB-EP748373DOT1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii pH-response regulator protein palH/RIM21 (RIM21), partial CSB-YP748374DOT1
CSB-EP748374DOT1
CSB-BP748374DOT1
CSB-MP748374DOT1
CSB-EP748374DOT1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Protein transport protein SEC23 (SEC23), partial CSB-YP748375DOT
CSB-EP748375DOT
CSB-BP748375DOT
CSB-MP748375DOT
CSB-EP748375DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×